Gelesis Holdings, Inc. (GLSHQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gelesis Holdings, Inc. (GLSHQ) with AI Score 65/100 (Buy). Gelesis Holdings, Inc. is a biotherapeutics company focused on developing treatments for obesity and GI-related chronic diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Gelesis Holdings, Inc. (GLSHQ) Healthcare & Pipeline Overview
Gelesis Holdings, Inc. was a commercial-stage biotherapeutics company focused on developing treatments for obesity and gastrointestinal disorders, most notably its weight management aid, PLENITY. The company's innovative approach using biomimicry aimed to address the underlying causes of these chronic conditions before filing for Chapter 7 liquidation.
Investment Thesis
Gelesis Holdings, Inc. presented an investment case centered on its innovative biomimicry approach to treating obesity and GI-related disorders. The company's lead product, PLENITY, had the potential to capture a significant share of the weight management market. However, the company's negative gross margin of -61.4% and negative free cash flow of $-0.00B indicated significant financial challenges. The high beta of 3627.55 suggested extreme volatility. The Chapter 7 liquidation filing in October 2023 represents a complete loss of investment for shareholders, as the company's assets are being liquidated to pay off creditors.
Based on FMP financials and quantitative analysis
Key Highlights
- Negative Gross Margin: Gelesis Holdings, Inc. reported a gross margin of -61.4%, indicating that the cost of goods sold exceeded revenue.
- Negative Free Cash Flow: The company's free cash flow was $-0.00B, highlighting its inability to generate positive cash flow from operations.
- High Beta: With a beta of 3627.55, the stock exhibited extremely high volatility compared to the overall market.
- Chapter 7 Liquidation: On October 30, 2023, Gelesis Holdings, Inc. filed for Chapter 7 liquidation, signaling the end of its operations.
- No Dividend: The company did not offer a dividend, reflecting its financial instability.
Strengths
- Innovative biomimicry technology.
- PLENITY's novel mechanism of action.
- Pipeline of product candidates (prior to bankruptcy).
Weaknesses
- Negative gross margin.
- Negative free cash flow.
- Reliance on a single product (PLENITY) for revenue.
- Chapter 7 liquidation filing.
Risks
- Ongoing: Chapter 7 Liquidation: The ongoing liquidation process poses a significant risk to any remaining assets or potential future value.
- Potential: Competition: The weight management and GI therapeutics markets are highly competitive, with numerous companies developing competing products.
- Potential: Regulatory Risks: The development and commercialization of pharmaceutical products are subject to strict regulatory requirements.
- Ongoing: Financial Instability: The company's bankruptcy filing highlights the risks associated with financial instability and the inability to generate sustainable revenue.
Growth Opportunities
- Expansion of PLENITY: Prior to its bankruptcy filing, Gelesis aimed to expand the market reach of PLENITY, its weight management aid. The weight management market is estimated to be worth billions of dollars globally, with a growing demand for non-prescription and non-systemic solutions. Gelesis's strategy involved increasing awareness and accessibility of PLENITY through partnerships with healthcare providers and direct-to-consumer marketing. However, the company's liquidation has halted these expansion efforts.
- Development of GS200 for Prediabetes and Type 2 Diabetes: Gelesis was developing GS200 as a potential treatment for weight loss in individuals with prediabetes and type 2 diabetes. This represents a significant market opportunity, as the prevalence of diabetes continues to rise globally. The company's biomimicry approach could have offered a novel mechanism of action compared to existing diabetes medications. However, the development of GS200 has been discontinued due to the bankruptcy filing.
- Advancement of GS500 for Functional Constipation: Gelesis was also working on GS500 for the treatment of functional constipation. Functional constipation is a common GI disorder affecting millions of people worldwide. The company's approach aimed to address the underlying causes of constipation by modulating the gut microbiome. However, the development of GS500 has been terminated as a result of the liquidation.
- Pre-clinical Development of GS300 for NAFLD/NASH: Gelesis had a pre-clinical program, GS300, targeting non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). NAFLD and NASH are growing health concerns, with limited treatment options currently available. The company's biomimicry platform could have offered a potential therapeutic approach. However, the pre-clinical development of GS300 has been halted due to the bankruptcy.
- Partnerships and Licensing Agreements: Gelesis could have pursued partnerships and licensing agreements to expand the reach of its products and technologies. Collaborating with larger pharmaceutical companies or medical device manufacturers could have provided access to additional resources and expertise. However, the company's financial difficulties and subsequent bankruptcy filing made it challenging to attract potential partners.
Opportunities
- Expansion of PLENITY's market reach (prior to bankruptcy).
- Development of new product candidates (prior to bankruptcy).
- Partnerships and licensing agreements (prior to bankruptcy).
Threats
- Competition from other weight management products.
- Regulatory hurdles for new product approvals.
- Financial instability leading to bankruptcy.
- Patent expiration risks.
Competitive Advantages
- Proprietary Biomimicry Technology: Gelesis's biomimicry platform represented a unique approach to treating obesity and GI disorders.
- PLENITY's Novel Mechanism of Action: PLENITY's non-stimulant, non-systemic mechanism of action differentiated it from other weight management products.
- Pipeline of Product Candidates: Gelesis had a pipeline of product candidates targeting various GI-related conditions (prior to bankruptcy).
About GLSHQ
Gelesis Holdings, Inc., incorporated in 2006 and headquartered in Boston, Massachusetts, was a biotherapeutics company dedicated to developing novel treatments for obesity and GI-related chronic diseases. The company's core technology revolved around biomimicry, creating therapies that mimic natural biological processes to address the root causes of these conditions. Their flagship product, PLENITY, was an orally administered, non-stimulant, and non-systemic aid for weight management, designed to help individuals feel fuller and eat less. In addition to PLENITY, Gelesis was developing a pipeline of product candidates, including GS200 for weight loss in prediabetes and type 2 diabetes, GS500 for functional constipation, and GS300, a pre-clinical product for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). However, on October 30, 2023, Gelesis Holdings, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, effectively ceasing operations and development efforts.
What They Do
- Developed PLENITY, an oral weight management aid.
- Utilized biomimicry technology to treat obesity and GI disorders.
- Developed GS200 for weight loss in prediabetes and type 2 diabetes (discontinued).
- Developed GS500 for functional constipation (discontinued).
- Developed GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (pre-clinical, discontinued).
- Filed for Chapter 7 liquidation in October 2023.
Business Model
- Focused on developing and commercializing prescription and over-the-counter therapies.
- Utilized a biomimicry platform to create novel treatments.
- Sought partnerships and licensing agreements to expand product reach (prior to bankruptcy).
Industry Context
Gelesis Holdings, Inc. operated within the biotechnology sector, specifically targeting the obesity and GI-related disease market. This market is characterized by a growing prevalence of obesity and related conditions, driving demand for innovative treatments. However, the biotechnology industry is highly competitive, with numerous companies developing pharmaceutical and medical device solutions. Gelesis's bankruptcy filing highlights the challenges faced by companies in this sector, including the high costs of research and development, regulatory hurdles, and the need for strong commercial execution.
Key Customers
- Individuals seeking weight management solutions.
- Patients with prediabetes and type 2 diabetes (potential customers for GS200).
- Patients with functional constipation (potential customers for GS500).
- Healthcare providers prescribing weight management aids.
Financials
Chart & Info
Gelesis Holdings, Inc. (GLSHQ) stock price: Price data unavailable
Latest News
No recent news available for GLSHQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GLSHQ.
Price Targets
Wall Street price target analysis for GLSHQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates GLSHQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
GLSHQ OTC Market Information
GLSHQ trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
What Investors Ask About Gelesis Holdings, Inc. (GLSHQ)
What does Gelesis Holdings, Inc. do?
Gelesis Holdings, Inc. was a biotherapeutics company focused on developing and commercializing novel treatments for obesity and GI-related chronic diseases. Their primary product, PLENITY, was an orally administered weight management aid designed to help individuals feel fuller and eat less. The company also had a pipeline of product candidates targeting prediabetes, type 2 diabetes, and functional constipation. However, Gelesis filed for Chapter 7 liquidation in October 2023, ceasing its operations and development efforts.
What do analysts say about GLSHQ stock?
Given that Gelesis Holdings, Inc. has filed for Chapter 7 liquidation, analyst coverage is likely to be minimal or non-existent. The stock is unlikely to be actively traded or followed by institutional investors. Any remaining trading activity would likely be driven by speculation or retail investors. The company's financial difficulties and bankruptcy filing suggest a high degree of risk and uncertainty.
What are the main risks for GLSHQ?
The primary risk for Gelesis Holdings, Inc. is its Chapter 7 liquidation filing. This means that the company's assets are being liquidated to pay off creditors, and there is little to no prospect of recovery for shareholders. Other risks include competition from other weight management products, regulatory hurdles for new product approvals (prior to bankruptcy), and the company's financial instability, which ultimately led to its demise.
How did Gelesis Holdings, Inc. manage intellectual property?
Gelesis relied on patents and proprietary technology to protect its intellectual property, particularly its biomimicry platform and the composition of PLENITY. The strength and breadth of these patents were crucial for maintaining a competitive advantage and attracting potential partners. However, the company's bankruptcy filing may impact the value and enforceability of its intellectual property assets, as they may be subject to sale or assignment during the liquidation process.
What revenue streams did Gelesis Holdings, Inc. have in healthcare?
Gelesis Holdings, Inc.'s primary revenue stream was the sale of PLENITY, its weight management aid. The company generated revenue through direct-to-consumer sales, partnerships with healthcare providers, and distribution agreements with retailers. However, the company's revenue was insufficient to cover its operating expenses, resulting in negative gross margins and free cash flow. The company's bankruptcy filing indicates that its revenue model was not sustainable in the long term.
What are the key factors to evaluate for GLSHQ?
Gelesis Holdings, Inc. (GLSHQ) currently holds an AI score of 65/100, indicating moderate score. Key strength: Innovative biomimicry technology.. Primary risk to monitor: Ongoing: Chapter 7 Liquidation: The ongoing liquidation process poses a significant risk to any remaining assets or potential future value.. This is not financial advice.
How frequently does GLSHQ data refresh on this page?
GLSHQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GLSHQ's recent stock price performance?
Recent price movement in Gelesis Holdings, Inc. (GLSHQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative biomimicry technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's bankruptcy filing.